CORPORATE PROFILE

The Foundation
In 2010, Bryogen Pharmaceuticals was founded by a group of Physicians, pharmacists and entrepreneurs to be more than a business firm that aims at profit. Bryogen was founded to be an influential organization in the Indian pharmaceutical market and industry. It is a company with a unique orientation, a philosophy and a clear future vision.

Corporate Philosophy

Bryogen recognizes itself as a business organization with a mission, not merely an entity that exists to generate profit. This mission describes the road map towards reaching long-term objectives and establishing the organization's future vision. Moreover, it highlights the basis and values that control business conduct on all levels.

Moreover, a clear future vision accessible to all company employees is an important element in portraying the desired shape of the organization in the future and therefore inspires, motivates and improves performance. This is why we keep our mission and vision in mind and heart at all times.

Our Mission

Bryogen provides high quality scientific products of recently discovered molecules at affordable prices, offering human medications that meet international quality standards. In this endeavor, Bryogen is committed to alliances with highly ranked technology providers, suppliers and manufacturers.

We view patients' wellbeing as the core of our business and our ultimate goal, placing ethics, values and responsibility towards related groups at the top, on our list of priorities.

Charged With Ambition

Charged with ambition, enthusiasm, confidence and commitment, believing in our ability to achieve and accomplish, Bryogen shall march towards its aspirations and reach them.

Our Vision

Bryogen shall known among healthcare professionals as a unique pharmaceutical company providing reliable products, and among patients as a company offering high quality medications. Bryogen shall recognized by everyone as a company that fulfills its responsibilities towards the society and plays an active role in many sectors. (2011-12) Bryogen shall be highly ranked among local companies, will grasping a significant share of the local market, demonstrating excellence in export, and is an attractive employer in the pharmaceutical market. (2013-15) Bryogen owns a modern manufacturing plant that will using the most recent technologies, applying the highest quality standards and is certified by international quality certifiers enabling penetration of numerous international markets. Bryogen works efficiently in many countries and is clearly distinguished; keeping that same image that has been imprinted in customers' minds along the years.

Research And Developement

Research and Development is a part of our strategy to become an integrated pharmaceutical industry. We believe R & D is of critical importance in our need to grow in the area of biotechnology and original drug research

Formulation Development :

The aim here is to devise formulations and dosage forms for new drugs to be introduced and to make variants of particular dosage forms. Another objective is to introduce drug combinations by understanding the mechanism of the interaction and the combined effects in increasing intensity of response, in decreasing untoward actions and in altering absorption.

New Drug delivery System :

The development of new delivery systems like nanoparticles and controlled drug delivery systems to ensure better compliance, less total drug, efficiency in treatment and economy.

Bio-equivalence studies :

Bryogen Pharmaceuticals is driven by it Vision to achieve significant business in proprietary prescription products with a strong presence in the pharma market. Bryogen Pharmaceuticals is eyeing upon better health achievement through effective and safe medicines based on technological innovation. Achieving customer satisfaction is fundamental to our business.

Process Developement:

One of our key objectives has been to develop indigenous processes for new drugs introduced in the developed countries, produce and introduce them in lots of countries and promptly supply them to non-regulatory markets.